0
0
A groundbreaking new device developed by researchers at Karolinska Institutet in Sweden offers a promising non-invasive method to detect tuberculosis (TB) by capturing and analyzing TB DNA from exhaled breath aerosols. This innovation has the potential to revolutionize TB diagnosis, especially where sputum samples are difficult to obtain, such as in children or patients unable to produce mucus for traditional tests.
Tuberculosis, an airborne infectious disease caused by Mycobacterium tuberculosis, remains a major global health challenge. Typically, TB diagnosis requires analysis of sputum—mucus coughed up from the lungs. However, many patients struggle to produce sputum, complicating timely detection and treatment. The novel device, named TB Hotspot detectOR (THOR), collects exhaled aerosols through electrostatic sampling, enabling detection of the bacterial DNA directly from patients’ breath.
In a study published on October 7, 2025, in the peer-reviewed journal Open Forum Infectious Diseases, researchers reported their findings from primary care clinics in South Africa involving 137 adults diagnosed with TB. Using the THOR device combined with the Xpert MTB/RIF Ultra assay (the same molecular diagnostic technique used for sputum samples), the researchers found that the method detected tuberculosis DNA in exhaled air in 47% of those who had tested positive via sputum. In cases with high bacterial loads, sensitivity improved to 57%, while the specificity—correctly identifying those without disease—was 77%.
Jay Achar, a researcher at Karolinska Institutet’s Department of Global Public Health and co-lead author of the study, emphasized the significance of the findings: “It is promising that we can detect infectious tuberculosis directly in the air, especially in settings where sputum samples are difficult to obtain.” He added that the method could help identify infectious individuals earlier, improving transmission control.
The study also revealed interesting insights about patient factors influencing detection. Men with high bacterial loads were more likely to have TB DNA detected in their exhaled breath, while those presenting with fever were somewhat less likely to test positive in breath samples. Additionally, TB DNA was detected in 30% of environmental samples in clinic settings, underscoring the potential risk of transmission in healthcare environments despite rigorous cleaning.
This research aligns with the growing body of literature supporting the use of non-sputum samples for TB diagnosis. Previous studies have explored saliva, oral swabs, and exhaled breath condensate as sample sources, highlighting advantages of easy collection, non-invasiveness, and suitability for vulnerable groups like children and people living with HIV/AIDS. However, deploying effective, sensitive diagnostics for these samples remains challenging.
The THOR device, by capturing aerosols based on electrostatic principles, represents an innovative solution to these challenges. It offers a potentially faster, simpler alternative to sputum collection, which can be distressing, especially for children or severely ill patients. Moreover, the ability to detect TB DNA in the environment also aids in understanding transmission risks and improving infection control measures.
While the new method shows promise, researchers caution that sensitivity is moderate, indicating it may not yet replace sputum testing but serve as a complementary tool. Further multi-center research with larger and more diverse populations is necessary to validate the findings, optimize the device, and evaluate cost-effectiveness in real-world healthcare settings.
For healthcare professionals, this innovation suggests an additional frontline diagnostic option that could increase TB detection rates, especially where sputum collection is impractical. For the public, the development points toward less invasive and potentially more accessible testing methods that could facilitate earlier diagnosis, timely treatment, and reduced transmission.
As TB remains one of the deadliest infectious diseases worldwide, with WHO estimating millions of cases annually, advancements like the THOR device signify progress toward global TB control goals. Continued research and investment in such innovative diagnostics will be crucial to curb TB morbidity and mortality.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
